您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 德国药房
产地国家: 德国
所属类别: 罕见病治疗药物->苯丙酮尿症
处方药:处方药
包装规格: 100毫克/片 120片/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
默克
生产厂家英文名:
Merck Serono GmbH.
该药品相关信息网址1:
http://www.kuvan.com/
该药品相关信息网址2:
http://www.bmrn.com/products/kuvan.php
该药品相关信息网址3:
http://www.rxlist.com/kuvan-drug.htm
原产地英文商品名:
KUVAN 100mg/tab 120tabs/bottle
原产地英文药品名:
SAPROPTERIN DIHYDROCHLORIDE
中文参考商品译名:
科望 100毫克/瓶 120片/瓶
中文参考药品译名:
盐酸沙丙蝶呤
原产地国家批准上市年份:
2007/12/13
英文适应病症1:
PKU
英文适应病症2:
HPA
临床试验期:
完成
中文适应病症参考翻译1:
苯丙酮尿症
中文适应病症参考翻译2:
高苯丙氨酸血症
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201181422060215.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文科望处方资料(仅供参考)

治疗罕见病新药Kuvan上市
总部位于瑞士日内瓦的默克集团的最大子公司默克—雪兰诺日前宣布,欧洲委员会已批准该公司生产的新药Kuvan——可用于治疗苯丙酮尿症(PKU)或高苯丙氨酸血症(HPA)——上市。此前欧洲药物审评局向Kuvan颁发了孤儿药证书。孤儿药是指用于罕见病、但商业价值较小、没有药厂愿意投资开发的药物。在美国或欧盟获得孤儿药资格的药物,可得到减税等优惠。

该公司副总裁Roberto Gradnik说:“PKU是一种遗传性疾病,如果患者没能严格控制饮食,PKU能够导致儿童脑部严重受损,导致成人暂时性甚至永久性的损害。欧洲一直没有可用于PKU治疗的药物。Kuvan上市后将为患者提供有效的治疗,更好地控制患者的血苯丙氨酸水平,有助于提高患者的生活质量,并可能最终减少脑部持续受损的风险。”

全欧大约35000人被确诊患有PKU或HPA,PKU或HPA发病率低,患者人数少,因此是一种罕见病。由于患者血液中苯丙氨酸水平过高,因此,严格限制苯丙氨酸含量较高的食品,如肉类、鱼类、坚果、乳类制品以及部分蔬菜和水果等,并补充氨基酸的饮食仍然是目前患者所能选择的唯一疗法,但长期下去可能会造成患者营养不良。

两项大型国际性双盲随机安慰剂对照Ⅲ期临床试验结果表明,Kuvan能够降低血苯丙氨酸水平,增加血苯基丙氨酸浓度处于目标范围内的患者数量,从而提高患者对于饮食中苯丙氨酸的耐受性,有助于减轻饮食中苯丙氨酸的限制。

欧洲委员会已为Kuvan颁发了在欧盟27个国家以及冰岛、列支敦士登和挪威的市场授权,其治疗适应症将在欧盟获得10年的保护。Kuvan预计将于今年上半年在欧洲上市。

默克认为Kuvan极具发展潜力,成为治疗这一罕见疾病的新药。据估计,在发达国家有50000人患有PKU,而他们中间30%-50%的人可以选择这种药物进行治疗。HPA的特征是患者体内血液中的苯丙氨酸含量增加,这会使神经细胞中毒,若不加以治疗,最终会导致脑损伤。

Kuvan® (sapropterin dihydrochloride) Tablets for PKU
KUVAN® (sapropterin hydrochloride) Tablets is the first and only FDA-approved medication for PKU to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4-) responsive PKU. Kuvan is a pharmaceutical formulation of BH4, the natural cofactor for the PAH enzyme, which stimulates activity of the residual PAH enzyme to metabolize Phe into tyrosine. Kuvan is to be used in conjunction with a Phe-restricted diet.

Kuvan at a Glance
•Approved in the United States, European Union, and Japan
•Designated an orphan drug in the United States and European Union
•Manufactured and commercialized by BioMarin in the United States

Regulatory Status
In December2007, Kuvan received marketing approval from the US Food and Drug Administration making it the first specific therapy for the treatment of PKU patients. A year later, Kuvan received approval in the European Union in December 2008. Kuvan has been designated an orphan drug in the US and EU, which grants market exclusivity for 7 and 10 years, respectively. (Biopten) was approved for PKU in Japan in July 2008.

Commercialization Plan
Kuvan is commercialized by BioMarin in the United States, Merck Serono in the European Union, and Asubio Pharma Co., Ltd. in Japan.

Full Indication and Important Safety Information (United States)
KUVAN® (sapropterin dihydrochloride) Tablets is approved to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used with a Phe-restricted diet.

Important Safety Information
High blood Phe levels are toxic to the brain and can lead to lower intelligence and decrease in the ability to focus, remember and organize information. Any change you make to your diet may impact your blood Phe level. Follow your doctor’s instructions carefully. Your doctor and dietitian will continue to monitor your diet and blood Phe levels throughout your treatment with KUVAN.

If you have a fever, or if you are sick, your Phe level may go up. Tell your doctor and dietitian as soon as possible so they can see if they have to adjust your treatment to help keep your blood Phe levels in the desired range.

KUVAN is a prescription medicine and should not be taken by people who are allergic to any of its ingredients. Tell your doctor if you have ever had liver or kidney problems, are nursing or pregnant or may become pregnant, have poor nutrition or are anorexic. Your doctor will decide if KUVAN is right for you. Tell your doctor about all the medicines you take.

The most common side effects reported when using KUVAN are headache, diarrhea, abdominal pain, upper respiratory tract infection (like a cold), throat pain, vomiting, and nausea.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201181422060215.pdf)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2013-01-17
附件:






201181422060215.PDF    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com